ClinicalTrials.gg
RecruitingNCT06914245TreatableUpdated Jan 23, 2026

Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients_contributing Factors (Treatable)

An interventional study of Electronic bowel diary and Faecal Incontinence Quality of Life questionnaire (FIQL) in Rectal Cancer, LARS - Low Anterior Resection Syndrome and Active Surveillance, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by KU Leuven · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Rectal Neoplasms with a site in Belgium — 10 open to participants now, 20 under way, 4 of them phase 3. Rectal Neoplasms · Belgium.

Planned enrollment
24th of 45
150 · median 156
Started
2025
with 3 others
No phase
13 of 56
5 open now
Primary completion
2028-12
later than 13 of 19 live
Registered
53rd of 56
by date
Lead sponsor
2 of 56
KU Leuven

Among the 56 studies in Rectal Neoplasms with a site in Belgium, this one is the 24th largest by planned enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 with no phase, reaches primary completion later than 13 of the 19 other live ones, and was the 53rd registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

10 of the 56 studies in Rectal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Rectal Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection combined with chemoradiotherapy. However, this treatment negatively affects various aspects of bowel function and patients' quality of life. These bowel symptoms often remain prevalent, even 12 months after RC treatment.

The aim of this study is to identify the factors contributing to persistent bowel symptoms and their long-term impact on quality of life following treatment for rectal cancer, assessed 12 months after surgery or stoma closure in surgically treated patients, and 12 months after completion of neoadjuvant therapy in patients managed with active surveillance/watch-and-wait. These insights are crucial for developing an effective care approach, as they help determine when specific evaluations should be conducted and which treatments should be applied at different stages.

03

Conditions studied

  • Rectal Cancer
  • LARS - Low Anterior Resection Syndrome
  • Active Surveillance

Keywords

  • Bowel diary
  • Quality of Life (QoL)
  • Care pathway
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  • At least 18 years of age at the time of signing the Informed Consent Form (ICF).
  • Proficient in reading, comprehending, and conversing in Dutch.
  • Patients scheduled for Total Mesorectal Excision (TME) or Partial Mesorectal Excision (PME) or 'Watch and wait' protocol due to rectal cancer.

Exclusion criteria

Exclusion Criteria:

  • The participant has undergone a different type of surgery, including a Hartmann procedure, abdominoperineal excision, transanal endoscopic microsurgery, or sigmoid resection.
  • Experienced fecal incontinence prior to undergoing surgery.
  • Are affected by neurological disorders affecting bowel function.
  • Already underwent previous pelvic radiation or rectal surgery for non-cancer reasons.
  • Has a permanent stoma.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    TME/PME

    To investigate the prognostic variables of persistent bowel symptoms and persistent consequences of bowel symptoms, specifically the impact on QoL, participants scheduled for rectal surgery will be asked to complete an electronic bowel diary on their mobile phones and to fill out several online questionnaires at multiple time points (prior to surgery, and at 1, 6, and 12 months post-rectal surgery or post-stoma closure).

    Diagnostic Test: Electronic bowel diary · Diagnostic Test: Faecal Incontinence Quality of Life questionnaire (FIQL) · Diagnostic Test: EuroQoL 5 dimensions, 5 levels (EQ-5D-5L)

  • Experimental
    Active surveillance

    To investigate the prognostic variables of persistent bowel symptoms and persistent consequences of bowel symptoms, specifically the impact on QoL, participants in active surveillance will be asked to complete an electronic bowel diary on their mobile phones and to fill out several online questionnaires at multiple time points (at baseline and at 1, 6, and 12 months after completion of neoadjuvant therapy).

    Diagnostic Test: Electronic bowel diary · Diagnostic Test: Faecal Incontinence Quality of Life questionnaire (FIQL) · Diagnostic Test: EuroQoL 5 dimensions, 5 levels (EQ-5D-5L)

Interventions

  • Diagnostic testElectronic bowel diary

    This bowel diary will be available on the smartphone in the form of an application.

  • Diagnostic testFaecal Incontinence Quality of Life questionnaire (FIQL)

    This questionnaire will be available online.

  • Diagnostic testEuroQoL 5 dimensions, 5 levels (EQ-5D-5L)

    This questionnaire will be available online.

06

What researchers measure

Primary outcomes

  1. Bowel symptoms after rectal cancer treatment

    To ensure that patients can report all their bowel symptoms where they suffer from, a valid, reliable, user-friendly, and easy-to-interpret electronic bowel diary has been developed in another research project for which approval has already been obtained from the Ethical Committee of the University Hospitals Leuven (S68746). This electronic bowel diary will be used to map out all bowel complaints.

    Time frame: 12 months

  2. The evaluation of Quality of Life (QoL) related to bowel symptoms after rectal cancer treatment

    Faecal Incontinence Quality of Life questionnaire (FIQL) will be used for the evaluation of QoL related to faecal incontinence problems. The FIQL is a reliable and valid 41-item questionnaire, resulting in 4 subscales: Lifestyle, Coping/behavior, Depression/Self Perception and Embarrassment. The Scales ranges from 1 to 5, with a 1 indicating a lower functional status of quality of life. This questionnaire is also validated in Dutch.

    Time frame: 12 months

  3. The evaluation of overall Quality of Life (QoL) after rectal cancer treatment

    EuroQol 5 Dimensions, 5 Levels (EQ-5D-5L) will be used to assess overall quality of life (QoL). The EQ-5D-5L is a reliable and valid 6-item questionnaire, consisting of two parts: the social perspective and the individual perspective of one's own health. In the social perspective, the health state is converted into a value set with a score ranging from 0 to 1, where 0 represents being dead and 1 represents full health. The individual perspective assesses the respondent's own perception of their health, with a score ranging from 0 to 100. This questionnaire is validated in Dutch and widely used to measure general health-related quality of life.

    Time frame: 12 months

Secondary outcomes

  1. The predictive value of 'defecation functions' measured with the MSKCC-BFI for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Defecation functions will be assessed with the Memorial Sloan-Kettering Cancer Centre Bowel Function Instrument (MSKCC-BFI). The MSKCC-BFI is a broad bowel specific questionnaire (18 items), resulting in three subscales, four single items and one total score for bowel function.

    Time frame: 12 months

  2. The predictive value of 'defecation functions' measured with the LARS score for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Defecation functions will be assessed with the LARS score. The LARS score is a short questionnaire, consisting of 5 items, stratifying patients into no, minor or major LARS. This questionnaire has been validated in Dutch.

    Time frame: 12 months

  3. The predictive value of 'defecation functions' measured with the PAC-SYM for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Defecation functions will be assessed with the Patient Assessment of Constipation-Symptoms questionnaire (PAC-SYM). The PAC-SYM is a validated constipation-specific questionnaire of 12 items that reflect stool, rectal and abdominal symptoms. Patients report the severity of each symptom on a Likert scale from 0 (absent) to 4 (very severe). This questionnaire has been validated in Dutch.

    Time frame: 12 months

  4. The predictive value of 'baseline age' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Information concerning the patient age will be derived from the medical file.

    Time frame: pre-operatively, prior to the surgical intervention for rectal cancer

  5. The predictive value of 'gender' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Information concerning the gender of the patient will be derived from the medical file.

    Time frame: pre-operatively, prior to the surgical intervention for rectal cancer

  6. The predictive value of 'diabetes' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Information concerning diabetes will be derived from the medical file.

    Time frame: pre-operatively, prior to the surgical intervention for rectal cancer

  7. The predictive value of 'smoking history' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Information concerning smoking history (current, former, never) will be queried.

    Time frame: pre-operatively, prior to the surgical intervention for rectal cancer

  8. The predictive value of 'BMI' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Information regarding the patient's BMI will be collected pre-operatively.

    Time frame: pre-operatively, prior to the surgical intervention for rectal cancer

  9. The predictive value of 'depression' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Depression will be measured using the Patient Health Questionnaire (PHQ-9), a 9-item validated Dutch questionnaire with scores ranging from 0 to 27. Higher scores indicate more severe depression, classifying patients into mild, moderate, moderately severe, or severe depression.

    Time frame: 12 months

  10. The predictive value of 'anxiety' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Anxiety will be assessed using the Generalized Anxiety Disorder-7 (GAD-7), a 7-item validated Dutch questionnaire with a score range of 0 to 21. Higher scores reflect greater anxiety severity, categorizing patients into mild, moderate, or severe anxiety.

    Time frame: 12 months

  11. The predictive value of 'resilience' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    Resilience will be measured using the Connor-Davidson Resilience Scale (CD-RISC), a 10-item questionnaire with scores ranging from 0 to 40, where higher scores indicate greater resilience. The scale was translated into Dutch using the forward-backward translation technique to ensure accuracy.

    Time frame: 12 months

  12. The predictive value of 'Optimal physiotherapy care' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    The assessment of optimal physiotherapy care for bowel symptoms during and after RC treatment will be defined based on available scientific evidence, guidelines and clinical expertise of the promotors of this project. Through a self-developed questionnaire, patients will be questioned which care they received in order to estimate by the research team whether they received no/suboptimal/optimal PT care.

    Time frame: at 6 months post-surgery or post-stoma closure

  13. The predictive value of 'Treatment-related factors' for the development of persistent bowel symptoms and consequences of bowel symptoms at 12 months post-surgery or post-stoma closure

    TNM-stage, tumor height, neoadjuvant therapy, stoma prior to surgery, date rectal cancer surgery, approach rectal resection, surgery technique, reconstruction technique, type of anastomosis, Rullier classification, inferior mesenteric artery ligation, inferior mesenteric vein ligation, type of stoma, date stoma closure, adjuvant therapy, post-operative complication, anastomotic leakage classification, Clavien-Dindo classification will be derived from the medical file.

    Time frame: At 1 month post-surgery or post-stoma closure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2028, 44 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 44 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 6, 2025
StartActual
Apr 28, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06914245
Lead sponsor
KU Leuven
Collaborators
AZ Delta, Universitair Ziekenhuis Brussel, Ziekenhuis aan de Stroom, AZ Oostende, General Hospital Groeninge, Regionaal Ziekenhuis Heilig Hart Tienen, Meander MC, Amersfoort, the Netherlands, AZORG, UZ Leuven, Leuven, Belgium
Responsible party
Inge Geraerts (Professor Dr., KU Leuven) — Principal investigator
First posted
Apr 6, 2025
Start date
Apr 28, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jan 23, 2026

Study contacts

Inge Geraerts, PhD
Contact
inge.geraerts@kuleuven.be
+3216329120
Liesbet Lauwereins, Msc.
Contact
liesbet.lauwereins@kuleuven.be
+3216379147
Inge Geraerts, PhD
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion